Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript

PresentationNajat KhanChief R&D Officer, Chief Commercial Officer and Director Hi, everyone, and welcome. I'm Najat Khan, Recursion's Chief R&D and Chief Commercial Officer and incoming CEO and President. Let's jump right in. Today is an important moment for Recursion, for our teams and most importantly, for the FAP patient community. We are here to share updated safety and efficacy results from our ongoing Phase I/II TUPELO study evaluating REC-4881 in FAP. Before we begin, please note that today's presen ...